CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
Earnings call transcript: Evercore Q4 2024 results beat expectations, stock rises
Evercore Partners Inc (NYSE:EVR) reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an EPS of $3.41 against a forecast of $3.04. The company also exceeded revenue ...
Evercore reports Q4 adjusted EPS $3.41, consensus $2.82
Reports Q4 adjusted revenue $980.5M, consensus $883.4M. John Weinberg, Chairman and Chief Executive Officer, “We are pleased with our ...
Modern Healthcare1d
VillageMD taps advisers as Walgreens pursues exit plan
Walgreens Chief Executive Officer Tim Wentworth reiterated on an earnings call last month that the company plans to divest ...
Evercore ISI Pounds the Table on Nvidia (NVDA) Stock Ahead of Earnings
Wall Street investment bank Evercore ISI (EVR) is pounding the table on Nvidia (NVDA) stock ahead of the chipmaker’s upcoming ...
Evercore ISI Issues Positive Forecast for Confluent (NASDAQ:CFLT) Stock Price
Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...
Morningstar4d
David Kamo Joins Evercore as Senior Managing Director in Investment Banking
Evercore (NYSE: EVR) announced today that David Kamo has joined the firm as a senior managing director to support its growing financial sponsor M&A advisory business,based in New York. “We are ...